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Estrogen plays an important role in skeletal physiology by maintaining a
remodeling balance between the activity of osteoblasts and osteoclasts. In an attempt
to decipher the mechanism through which estrogen elicits its action on the 7F2
osteoblast-like cell line, experimentation necessitated development of culturing
environment reduced in estrogenic compounds. The selected media (OPTI-MEM) is
enriched to sustain cultures under reduced fetal bovine serum (FBS) conditions. The
OPTI-MEM medium is devoid of the pH indicator phenol red (a suspected estrogenic
agent). This protocol reduced the concentration of FBS to 0% through successive,
24-hour incubations with diminishing amounts of supplemental FBS (1 %, 0.1 %, and
0% ). The newly developed protocol does not alter the viability, cell morphology, or
physiological nature of these osteoblast-like cells, when compared to control cells,
grown in various concentrations of FBS. Though the rate of 7F2 mitotic divisions
declined, the utilization of colorimetric ass_ays, immunohistochemical techniques, and
RT-PCR have verified that the cells still express osteoblast cell-specific markers.
Experimental results indicate that both low and high doses (O. lnM to l.9mM) of
estrogen 7F2 cells remain viable after 24-hour incubation, but that prolonged

exposure (48 hrs) to high concentrations results in cell death. This system was also
used to test the effect of the drug verapamil on bone cells. The calcium channel
antagonist verapamil has been suspected of eliciting its action directly on the
osteoblast but its exact effect is controversial and the mechanism is unknown.
Exposure of 7F2 cells to concentrations of verapamil ranging from I 0µM to 500µM
resulted in no loss of cell viability. Doses of verapamil greater than or equal to
600µM were toxic to the cells. These experimental findings suggest the culture
protocol developed has not altered the 7F2 cell line from its osteoblast-like nature and
provides a model system to study estrogen's antiresorptive role on skeletal turnover
and the potential impact of calcium channel antagonists on estrogen's mechanism of
action.
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INTRODUCTION

Bone, a specialized form of connective tissue, is composed of numerous cell
types, extracellular matrix and extracellular fluid. It provides the skeleton the
necessary tensile strength to support the body. The calcified extracellular matrix of
bone, the hardest material in the body, is not the only calcified tissue found in the
body; teeth also are calcified. Bone is large! y composed of collagen, protein, and
hydroxyapatite, an inorganic mineral composite. Bone functions as a reservoir for
various minerals like calcium, phosphate and magnesium, thus playing a role in the
homeostasis of these and various other minerals. Compounds like bicarbonate,
citrate, potassium, sodium are also present in bone. The bone matrix also contains
cytokines and growth factors which play important roles in various skeletal
physiological mechanisms (Ross et al., 1985; Marks et al., 1996; Compston, 2001).
Bone contains mesenchymal-derived osteogenic and hemopoietic cells. The
cells that make up this tissue in the body can be found lining the internal and external
surfaces of the bone and are referred to as endosteum and periosteum, respectively.
The periosteum is the structure which nourishes bone and is rich in capillaries.
Cross sectional examination of a bone allows for the differentiation of bone
into two general types: cortical (compact) and trabecular (cancellous) bone. Cortical
bone comprises 80% of the skeleton and is predominately found in the shafts of long
bones and the surfaces of flat bones. The remaining 20% is trabecular bone and is
predominantly found in the flat bones of the body or the end of the long bones. The

cortical bone is composed of tightly packed osteons or haversian canals. Osteons are
small structures which contain blood vessels, lymphatic tissue, and nerves surrounded
by numerous layers of connective tissue. Every osteon is perforated with spaces
called lacunae and these lacunae contain osteocytes, a bone cell. Trabecular bone is
very different from cortical bone because this bone type consists of thousands of
trabecule that interconnect forming a lattice-like network of bony spicules creating a
protective environment for hematopoietic tissue (Ross et al., 1985; Marks et al.,
1996; Junqueria et al., 2003).

Types of Bone Cells
Four types of cells are found in bone. These four types of cells are:
osteoblasts, which synthesize the organic component of bone matrix; osteoclasts,
involved in dissolving the calcified bone tissue; osteocytes, which are found in
lacunae throughout the calcified matrix and are the sensors of mechanical stress; and
the lining cells which are quiescent osteoblasts lining all bone surfaces. It is believed
that osteblasts, osteocytes and bone lining cells all originate from the same
osteoprogenitor.

Osteoblasts:
Osteoblasts are mainly responsible for the formation and mineralization of
bone and are derived from pluripotent mesenchymal stem cells. The osteoblastic
stem cells serve as the precursors for bone marrow stromal cells, muscle cells, and
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adipocytes (Pittenger et al., 1999). Mature and fully differentiated osteoblasts secrete
the proteins that constitute the bone matrix which will be mineralized over time. This
calcification process includes the formation of hydroxyapatite. Osteoblasts are
thought to control the levels of both calcium and phosphate in the bone
microenvironment leading to the formation of hydroxyapatite (Manolagas, 2000;
Compston, 2001). The major secretory product of osteoblasts is Type I collagen
which is assembled into collagen fibrils by extracellular proteolytic cleavage and
processing. Collagen molecules become interconnected through the production of
cross-linkers such as pyridinoline links. (Ross et al., 1985; Manolagas, 2000;
Compston, 2001; Junqueria et al., 2003).
Osteoblasts also synthesize and secrete a number of non-collagenous proteins
as a part of the bone matrix. Two such non-collagenous proteins are osteocalcin and
osteonectin. These two proteins constitute 40-50% of the total non-collagenous
protein. In addition, glycosarninoglycans which are ultimately attached to small core
proteins like PG-I (biglycan) and PG-II (decorin) are also synthesized by osteoblasts.
It is reported that decorin is involved in the regulation of collagen fibrillogenesis
(Manolagas, 2000; Compston, 2001).
Additionally, osteoblasts synthesize alkaline phosphatase. Alkaline
phosphatase is anchored to the external surface of the plasma membrane and is
presumed to play an instrumental role in the bone mineralization process (Manolagas,
2000); making alkaline phosphatase an important osteoblastic marker. It is
hypothesized that alkaline phosphatase alters the environment around the osteoblast
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comprised of the newly secreted matrix by raising the pH (Aubin et al., 1993). A
genetic deficiency in the production of alkaline phosphatase called hypophosphatasia
(Whyte, 1994) leads to a condition characterized by ineffective bone mineralization.

Osteocytes:

The osteocyte progenitors are mature, matrix-secreting osteoblasts.
Osteocytes, the mechanosensory cells of bone, play an active role in bone turnover.
When osteoblasts become embedded in the mineralized matrix that they generate,
they are referred to as osteocytes and the void they occupy is known as a lacuna.
Osteocytes have a stellate morphology which is reminiscent of the dendritic network
of the nervous system. During the differentiation of osteoblasts into mature
osteocytes, a considerable portion of the cytoplasmic organelles are lost. However,
substantial growth occurs generating numerous cellular processes that allow these
cells to communicate directly with other osteocytes, osteoblasts or lining cells.
The osteocytes communicate with each other or with other cells, via an
extensive network of dendrite-like cell extensions within fluid-filled channels called
canaliculi. The location of osteocytes within this fluid-filled network (encased by
calcified bone) and the fact that they are connected to each other, make osteocytes
perfectly situated to respond to mechanical stimuli and thus play the physiological
role of mechanosensors/transducers of bone (Klein-Nulend et al., 1995; Pitsilledas

et al., 1995).
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The mechanosensory nature of osteocytes is attributed to the fact that they are
able to detect the need for bone augmentation of the skeleton and thus initiate repair
following rnicrodamage (Marotti et al., 1990; Compston, 2001). There are ten times
more active osteocytes than osteoblasts in adult bone. It is believed that there is a
reduction in osteocyte number with age just as there is a loss in ovarian function. It
has been demonstrated that, in ovariectornized rats, osteocyte apoptosis is increased
in tibia rnicrosections (Tomkinson et al., 1998). This discovery may suggest that
estrogen's maintenance of the osteocyte population and, hence, its role bone
remodeling is critical.

During osteoclast resorption, the osteocytes may become phagocytic and
undergo apoptosis (Compston, 2001). Disruption of the osteocyte network which
results due to imbalance in bone turnover could lead to a compromised
mechanosensory mechanism leading to rnicrodamage accumulation of bone and
increased bone fragility. Bone tum-over is the activity through which bone mass is
maintained.

Osteoclasts:

Osteoclasts are the multinucleated cells involved in bone resorption.
Osteoclast progenitors are recruited from the hematopoietic tissue of the
monocyte/macrophage lineage. The number of osteoclasts is only a fraction of the
number of osteoblasts present in bone. These cells have a complex infolding of the
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plasma membrane and clear zones which help in the attachment of the osteoclasts to
bone surfaces. Osteoclasts are characterized by the presence of these villous
extensions of the plasma membrane called the ruffled border. The ruffled border
greatly increases osteoclast surface area. The resorbing area under the ruffled border
is acidic and, as a result of the exocytosis of secretory vesicles containing digestive
enzymes, helping in the dissolution of the bone mineral. Osteoclasts also secrete
lysosomal enzymes that degrade the organic matter of the bone (Suda et al., 1997).
Osteoclasts are predominately present in the small cavities called Howship lacunae.
Cytokines and growth factors are crucial for the differentiation of osteoclasts.
Calcitonin and bisphosphonates inhibit osteoclast differentiation (Ross et al., 1985;
Manolagas, 2000; Compston, 2001; Carnieo et al., 2003).

Lining cells:
Lining cells are also derived from osteoblasts. The generation of lining cells
occurs when osteoblastic function (bone formation)-is concluded in an active region
of bone remodeling. Lining cells form a layer/barrier between the general
extracellular fluid and the bone fluid environment. This cell type covers all surfaces
of bone that are quiescent (not undergoing bone remodeling) for both the periosteum
and endosteum. Morphologically, lining cells are flat, elongated cells which are in
direct contact/communication with osteocytes.
The targeting of the osteoclast precursors to a specific location within the
skeleton is thought to be mediated by a signal originating from the lining cells
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(Manolagas, 2000). It is thought that lining cells secrete a type of collagen which
forms a film on calcified bone where osteoclasts can attach (Manolagas, 2000;
Compston, 2001).

Cellular Physiology of Bone
The cellular process by which bone mass is maintained, is referred to as bone
remodeling. Bone remodeling takes place on all bone surfaces. During bone
remodeling, preostoclasts are stimulated to differentiate into mature osteoclasts under
the influence of cytokines. Osteoclasts create a bone cavity/depression through a
process called bone resorption. These depressions are later filled by osteoblasts with
bone matrix. The osteoblasts secrete Type I collagen which becomes mineralized,
completing the bone formation and resorption cycle. The balance between these
catabolic and anabolic processes maintains skeletal integrity. A resorptive imbalance
(remodeling imbalance) can occur if the osteoclasts generate excessively deep
resorption spaces or if osteoblasts fail to refill the resorption space completely
resulting in a loss in bone mass. A remodeling imbalance is the difference between
the amount of bone resorbed and the amount of bone formed (Ross et al., 1985;
Junqueria et al., 2003).

Estrogen Synthesis and Function
Estrogen, a C18 steroid, is produced from cholesterol in the reproductive
organs. Its precursor, cholesterol, can be derived from animal fat in the diet but it is
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also synthesized in the body. In females, estrogen is primarily produced in the
developing follicles, ovaries, corpus luteum and by the placenta (Griffin and Ojeda,
2004).
In the ovaries, other than progesterone, estrogen is the main steroid hormone

secreted. Both of these hormones are lipophillic and, through signal transduction
pathways, they regulate reproductive function in women. In addition to the
development of secondary sexual characters like breasts, estrogen also regulates the
menstrual cycle. Estrogen diffuses from the bloodstream passively and interacts with
its target cells. Like other steroid hormones, estrogen binds to specific cytoplasmic
receptors, forming a mobile cytoplasmic receptor steroid complex. This complex
translocates to the nucleus where it binds to non-histone proteins of the DNA to
activate the transcription of genes (Smith, 1994; Weiner et al., 1994). Follicle
stimulating hormone (FSH) and luteinizing hormone (LH) regulate the production of
estrogen in ovulating women. Circulating levels of estrogen are associated with
negative feedback loops that affect additional FSH and LH secrection and, ultimately,
the production of estrogen.
Though estrogen is mainly considered a female reproductive hormone, it is
also present in males, but at lower concentrations. In men, estrogen is considered
essential for the fusion of the epiphysis in bone and is important in bone mass
maintenance. The epiphysis is the thickened head present at each end of the bone.
Besides its normal reproductive function in men and women, estrogen is
known to have effects on the cardiovascular system, skeletal system and the nervous
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system (Lobo et al., 2000). The estrogen, 17~ estradiol, has been shown to inhibit the
calcium influx induced by thrombaxane A2 and in tum, inhibit the contraction of the
coronary vascular smooth muscles (Han et al., 1995). Additional effects on the
cardiovascular system are illustrated by estrogen's by ability to decrease circulating
LDL and to increase circulating HDL (Kushwaha and Hazzard, 1981).
Estrogen also acts as a neurohormone and its receptors have been found in the
various regions of the brain. Estrogen plays an important role in the sexual
differentiation of the human brain in early embryonic life and throughout neonatal life
(Griffin and Ojeda, 2004 ). The presence of estrogen receptors in various regions of
the brain indicates action other than sexual differentiation. It is also speculated that
estrogen may have effects on memory and learning (McEwen, 2002).

Estrogen's Mechanism of Action on Bone

The loss of bone mass below a critical threshold can lead to a non-traumatic
fracture. This non-traumatic fracture is the hallmark of the bone disease known as
osteoporosis, a disease predominantly found in woman (Riggs et al., 1981). It was
Fuller Albright who linked osteoporosis with estrogen deficiency after noting the
prevalence of the disease in postmenopausal women (Patlak, 200 I). By the
mid-1970's, like other steroid hormones, estrogen had been significantly linked to
bone remodeling in adult women. Estrogen's role is at least two-fold in normal
woman: it specifically suppresses cancellous bone remodeling and it regulates the
interaction between the activity of osteoblast and osteoclast cell types (Patriff, 1979).
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Estrogen is also recognized for initiating pubertal growth and, later in development,
for its limiting oflongitudinal bone growth by inducing the closure of the epiphysial
growth plate (Nilsson et al., 2001).
Postmenopausal changes in bone include an increase in both cortical and
trabecular bone destruction resulting in a weakened skeleton and increased fracture
risk (Seeman, 2002). Most of the rapid changes within the skeletal architecture due to
estrogen deficiency in postmenopausal woman are observed in trabecular bone
because of its huge surface area, however cortical bone is also significantly weakened
by estrogen deficiency (Vaananen et al., 1996). The lack of estrogen in
postmenopausal woman results in an imbalance between bone resorption and bone
formation that results in trabecular thinning and disconnections (Seeman, 2002).
Trabecular bone is primarily found in bones of the axial skeleton but is also present in
the appendicular skeleton, specifically in the ends of long bones. Trabecular thinning
and disconnections decrease the mechanical strength of bone. But some evidence
(from rat models) suggests that the loss of estrogen leads to bone loss accompanied
by osteoclast perforation of trabecular plates and ultimate!y their removal rather just
trabecullar thinning (Dempster et al., 1995). Once menopause is reached, there is an
increase in bone remodeling units (Patriff, 1979). Radiocalcium kinetics and external
calcium balance experiments also suggest that, in healthy women with menopause,
bone turnover is increased but bone resorption exceeds bone formation (Heaney et al., ·
1978; Patriff, 1979). There is evidence that estrogen at pharmacological dosages
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possesses the ability to reverse bone loss in postmenopausal women even at the age of
seventy (Prestwood et al., 1994).
Estrogen replacement at menopause prevents bone loss and is characterized by
an increase in bone mass density following the first 12-18 months of treatment
(Compston, 2001 ). It has also been noted that estrogen replacement therapy
associated with exercise induced an increase in bone mineral density in
postmenopausal woman, as compared to the control group (Gozansky et al., 2005).
Recently, it has been reported that even low levels of serum estrogen (6.5 pg/ml) in
postmenopausal women, can exert a protective effect on ones skeletal integrity
(Heshmati et al., 2002).
In long-term cultures of rat osteoblastic-like cells, 17P estradiol (estrogen)
stimulates cell proliferation in a dose-dependent-fashion. In in vitro osteoblast
cultures, estrogen increases the cell growth by two-fold (based on DNA content) and
also increases the expression of alkaline phosphatase and type I collagen (Majeska et

al., 1994). Both alkaline phosphatase and type I collagen are phenotypic markers of
osteoblastic differentiation and bone formation. Majeska et al. (1994) reported that
estrogen inhibits the activation of a cAMP-dependent pathway required for the bone
resorption processes initiated by parathyroid hormone and prostaglandin E 2 •
Similarly, Chow et al. (1992) showed that estrogen not only suppressess the bone
resorption cascade, but stimulates bone formation. Osteoblasts treated with estrogen
have reduced the production of factors like Interleukin-6 (IL-6) and Interleukin-! (IL1). These factors inhibit the differentiation of osteoclasts to a multinucleated
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osteoclastic cell type thereby decreasing their resorptive nature (Qu et al., 1999).
Estrogen also appears to inhibit osteoclastic bone resorption by mediating osteoclast
apoptosis through an estrogen receptor (ER) mediated mechanism (Kameda et al.,
1997). The further discovery of estrogen receptors in osteoblasts (Erik et al., 1980)
implies that osteoblasts are the direct target for estrogen. The number of available
estrogen receptors in various studies has varied from 45 to 45,000 binding sites per
osteoblast. This is considerably less than the number in estrogen-responsive
reproductive cells (Vanderschueren et al., 2004). Experiments in an immortailized
human fetal osteoblast cell line have revealed that estrogen receptors u (ERu) and ~
(ER~) mRNA are differentially expressed during osteoblast differentiation, with a
10-fold increase of ER~ expression during the mineralization period, as compared to
the proliferative phase (Arts et al., 1997).
At the cellular level in bone, estrogen inhibits the differentiation and recruitment
of osteoclasts, decreasing their number and in turn reducing the number of remodeling
regions (Vaananen et al., 1996). Fewer remodeling regions results in increased skeletal
mass. In contrast, various other studies suggest that the loss of estrogen also stimulates
bone formation, but that bone resorption still exceeds bone formation, ultimately
resulting bone loss (Parfitt et al., 1983, Poli et al., 1994). Estrogen prevents bone loss by
blocking the production of proinflarnatory cytokines from the bone marrow and bone
cells. Specific cytokines would lead to the expansion of the osteoclastic pool and
lengthen their life span.
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The cytokines known to be regulated by estrogen are IL-6 and IL-1 (Vaananen et

al., 1996). IL-6 increases bone resorption by activating the differentiation of immature
osteoclasts. Estrogen down-regulates the transcription of IL-6 (Galien et al., 1996), thus
decreasing bone resorption by inhibiting osteoclast differentiation. Genetic studies have
indicated that the IL-6 gene affects bone metabolism and increased expression of IL-6
leads to osteoporosis (Ota et al., 2001). The fact that IL-6-deficient ovariectomized mice
do not express osteoporosis (Poli et al., 1994) supports the hypothesis that estrogen is the
mediator of bone resorption. Estrogen inhibits the production of IL-6 by blocking the
transcription factor NF-K~ (Galien et al., 1996). Contrary to its resorptive activities, IL-6
has also been shown to induce the formation of alkaline phosphate in osteoblasts,
ultimately leading to osteoblast differentiation (Franchimont et al., 2005).
IL-1, another key mediator in osteoporosis, stimulates osteoclast cell survival
(Ralston, 1994). IL-1 stimulates the release of soluble factors from osteoblasts which
enhance osteoclast survival (Chambers et al., 1986). Estrogen induces the production of
an IL- I decoy receptor which decreases the expression of the factors that trigger
osteoblastic survival (Spelsburg et al., 1999). These sets of experiments strongly suggest
that IL-6 and IL-1 are active mediators of bone resorption and that estrogen is
antagonistic to IL-6 and IL-1. This hypothesis is further supported by the fact that, in
postmenopausal women, bone marrow cells release more bone resorbing cytokines as
estrogen levels fall (Bismar et al., 1995). The mechanism of action for these cytokines is
unclear at this time.
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Molecular Mode of Action of Estrogen on Bone
The action of hormones on osteoblasts initiates the expression of genes that play
various roles in bone resorption by affecting, osteoblast differentiation into osteoclasts.
The activity of estrogen on osteoblasts induces various molecular effects. Estrogen upregulates genes which play roles in the molecular mechanisms through which skeletal
integrity is maintained. The genes that play a significant role in skeletal physiology are
osteoprotegerin (OPG) and Transforming growth factor~ Inducible Early Gene (TIEG);
both of these genes are up-regulated by estrogen (Tau et al., 1997; Stejskal et al., 2001).
Receptor activator of nuclear factor kappa B ligand (RANKL), a transmembrane
receptor found in osteoblasts, is involved in the development of functional osteoclasts.
RANKL, a member of the Tumor Necrosis Factor (TNF) superfamily, interacts with
RANK, a transmembrane receptor present on the cell surface of the osteoclasts. The
RANK/RANKL complex enhances osteoclast activity and inhibits ostoeoclast apoptosis
(Lam et al., 2001; Riggs et al., 2002) and provides an essential signal for osteoclast
differentiation (Yasuda et al., 1998). RANKL supplementation in culture medium
activates mature osteoclasts in vitro, in a dose-dependent manner (Boyle et al., 2003),
while osteoprotegerin (OPG) a decoy receptor expressed by osteoblasts, prevents the
interaction of RANK with RANKL (Hsu et al., 1999). OPG competes with RANK,
blocking the differentiation and function of the osteoclasts. Estrogen up-regulates the
action of OPG at both the mRNA and protein levels. The absence of estrogen downregulates OPG, favoring osteoclast differentiation (Sakia et al., 2001). Furthermore, mice
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with an inactive OPG gene exhibit severe osteoporosis (Bucay et al., 1998; Jimi et al.,
1999).
Transforming Growth Factor p (TGF P) can stimulate the differentiation of
osteoblasts (Bonewald et al., 1994). TIEG

p, a member ofTGF pfamily, has been

reported to have osteoblastic activity because TIEG-negative mice are defective in
osteoblast-mediated mineralization (Subramaniam et al, .2005). In contrast, over
expression of TIEG leads to the inhibition of DNA synthesis in fetal human
osteoblasts and, thus, represses cell proliferation. In osteoblasts, estrogen rapidly
induces transcription ofTIEG mRNA, in a dose-dependent manner. Thus, TIEG is an
important participant in the pathway by which estrogen regulates DNA synthesis and
cell division, in these cell lines (Tau et al., 1997).

Calcium Channel Antagonists and Bone

Calcium plays an important role in bone metabolism. A portion of bone calcium
is mineralized in the form of hydroxaypatite in the extracellular matrix, while the other
portion is soluble. The soluble portion can be found both in the extracelluar fluid (bone
fluid) where it bathes the bone cells and within the cell where it participates in signal
transduction. There is a continuous exchange of soluble calcium that takes place through
the calcium channels of the plasma membrane. Calcium channels are present in the
plasma membrane of both osteoblasts and osteoclasts. The regulation of calcium
entry/exit through the activation of these plasma membrane channels appears to play a
significant role in bone metabolism because the rate of physiological bone resorption
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diminishes as serum concentrations of calcium increase (Ducan et al., 1998). The release
of calcium from bone is stimulated by parathyroid hormone (PTH) through these calcium
channels (Yamagichi et al., 1987; Barry et al., 1995; Ducan et al., 1998). Under the
influence of PTH and vitamin D3 , osteocalcin is secreted by osteoblasts. Osteocalcin, a
non-collagenous protein component of the bone matrix and biochemical indicator in bone
turnover, stimulates the resorptive activities of osteoclasts. Experimental studies have
suggested that PTH induces calcium influx through channels associated with
desmethoxyveraparnil receptors, a calcium channel antagonist's receptor (Guggino et al.,
1989).
Calcium channel antagonists are divided into 5 broad classes with diverse
chemical structures. They are i) Benzothiazepines: Diltiazem; ii) Dihydropyridines:
Nicardipine, Nifedipine; iii) Phenylalkylamines: Verapamil; iv) Diarylarninopropylamine
ethers: Bepridil; and v) Benzimidazole-substituted tetralines: Mibefradil. Calcium
channel antagonists were introduced in the 1960's for the treatment of cardiovascular
disease because they lower blood pressure (Abernethy et al., 1999). This action is
elicited by inhibiting the L-type voltage-dependant calcium channels in vascular smooth
muscle cells. The concentrations of the calcium channel antagonists required inhibit the
release of intracellular calcium or to block its entry into tissues is drug-dependent
(Redich et al., 1997; Abernethy et al., 1999).
The L-type voltage-sensitive channels also play an important role in the influx of
calcium ions in bone cells. They act in a way that interferes with the transfer of calcium
when they are closed, thus impacting the resorptive process (Guggino et al., 1989;
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Redlich et al., 1997; Duncan et al., 1998). L-type calcium channels are composed of 5
subunits (a1, a2, p, 'Y and o). The a 1subunit contains the pore through which calcium
passes, the voltage sensor, and is the site where calcium channel antagonists bind
specifically (Akanabi et al., 1998, Li et al., 2002). Guggino et al. (1989) have suggested
that calcium channel antagonists (e.g., verapamil, nifedipine) interfere with bone
resorption.

In hypertensive patients, verapamil is believed to suppress basal and I, 25dihydroxyvitamin D 3 stimulated alkaline phosphatase activity in osteoblast-like cells
(Sjoden et al., 1990). All theses studies indicate that veramapil has an effect on bone
formation. It has been reported that verapamil decreases mechanically-induced bone
formation on the endochondrial surface of the tibia (Li et al., 2002).

Statement of Problem
Experimentation will investigate the action of estrogen and verapamil on an
osteoblast like cell line (7F2 cell) through the utilization of a tissue culture method.
The proposed research will establish a tissue culture protocol in the absence of FBS
and phenol red, both of which are reported to be estrogenic in nature. Validation of
the developed protocol will require the 7F2 cell line to express its osteoblast-like
nature. This research will also try to determine the effect of 17P estradiol and
verapamil on cultured 7F2 cells with the newly developed protocol.
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MATERIALS AND METHODS

General Protocol for Culturing 7F2 Cells
A 7F2 cell line (osteosacroma/mouse osteoblast like cells) purchased from
American Type Culture Collection was grown in Dubleco's Modified Eagle's
Medium (DMEM) (Invitrogen Laboratories) supplemented with 10% Fetal Bovine
Serum (FBS) in typical tissue culture Cornmayer flasks (75 mm2). To avoid potential
bacterial contamination, 10 ml of penicillin-streptomycin solution was added to every
500 ml ofDMEM utilized. To make 10% PBS-supplemented DMEM, 50 ml ofFBS
(Invitrogen Laboratories) was added per bottle of DMEM. The medium was also
supplemented with an antibiotic solution containing penicillin (10,000 units) and
streptomycin (10 mg/ml) dissolved in sodium chloride (Sigma) at a concentration of
0.9%. Once the cells reached confluence, they were split between 3 flasks. The
splitting of 7F2 cells required a split solution prepared by mixing Phosphate Buffer
Saline (PBS) and Trypsin EDTA (5 g/100 ml) (Invitrogen), prepared at a 9: 1 ratio.
The PBS solution was prepared by autoclaving 2 PBS tablets (Sigma) in 400 ml of
distilled water. The split solution was added to the cells, following the aspiration of
culture medium, and incubated for 10 min at room temperature, with periodic
agitation against the palm of the hand, in order to enhance the stripping of cells from
the flask. The cells and the split solution were transferred to 15 ml conical tubes and
spun for 10 min at high speed. The supernatant was discarded and the pellet
resuspended in 3 ml of 10% PBS-supplemented DMEM. After complete
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resuspension, approximately 1 ml of the resuspended cells was added to each of three
new flasks possessing 25 ml of the DMEM. The cells were maintained in a Napco
incubator at 37°C with 5% CO2 • The cells were fed with 10% PBS-supplemented
DMEM (medium replacement) every 72 hrs. Once the cells reached confluence, as
outlined above, they were split.

Reduced FBS Protocol
Cell culture medium is typically provided with the nutrient supplement PBS
and PBS contains estrogen. The cells that were grown in 10% PBS-supplemented
DMEM medium were allowed to reach confluence and then they were passed to
various concentrations (10, 5, 3, and 1%) of PBS-supplemented DMEM (Figure 1).

7F2 Culture Protocol to Wean Cells from FBS and Phenol Red
7F2 cells grown in PBS-supplemented DMEM were switched to OPTI-MEM
(Invitrogen), an enriched medium devoid of phenol red. Transferring the cells from
10% PBS-supplemented DMEM to OPTI-MEM required a stepwise reduction of the
PBS concentration; i.e. the cells had to be weaned from PBS. 7F2 cells grown in
10% PBS-supplemented DMEM were passed (split) to 5% PBS-supplemented
OPTI-MEM upon reaching confluence as previously discussed. 7F2 cells were
allowed to grow to confluence, in the 5% PBS-supplemented OPTI-MEM and then
passed to 1% PBS-supplemented OPTI-MEM. Once the cells in 1%
PBS-supplemented OPTI-MEM reached confluence, they were passed to various
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Figure 1: Weaning of 7F2 cells from 10%-1 % FBS-supplemented DMEM.

1%

concentrations ofFBS-supplemented (0.5, 0.25, 0.1, 0.05 and 0%) OPTI-MEM in
small tissue culture flasks (25 mm)2 as shown in Figure 2.

Long Term Culturing of 7F2 Cells in a Reduced FBS Environment
7F2 cells were grown to confluence in 1% PBS-supplemented OPTI-MEM.
Then, the cells were passed and resuspended in 0.1 % PBS-supplemented OPTI-MEM
and distributed equally between 6 small flasks and combined with 4 ml of 0.1 %
PBS-supplemented OPTI-MEM. Following a 24 hr incubation, the medium was
aspirated and the cells were washed with 3 ml of sterile PBS and feed with medium
containing no PBS (0% OPTI-MEM). Subsequent washings occurred every 24 hr for

13 days (Figure 3). Prior to each wash, representative photographs of the cells were
taken to document cell viability/morphology using an Olympus CKX41 inverted
microscope fitted with an Olympus DP12-2 digital camera.

CellViability Assay
Cell viability for each day of the 13 day experiment was determined.
The medium was transferred from the flask to a 15 ml centrifuge tube. Three
milliliters of the split solution was used to strip cells from the flask walls. An
additional 3 ml of PBS was used to wash any remaining cells from the flask. The
resulting cell suspension was spun for 10 min at maximum speed. The pellet was
resuspended in 1.5 ml of 0% PBS-supplemented OPTI-MEM. One hundred
microliters of the resulting cell suspension was combined with 900 µL of a trypan
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Figure 2: Weaning of7F2 cells from 1 %-0% FBS-supplemented OPTI-MEM.

0%

Culture cells in 1 % OPTI-MEM
for 72 hrs

q

3

q

q
3

3

~

Culture cells in 0.1 % OPTI-MEM for 24 hrs

~

N

w

-=----3

Feed cells with 0% OPTI-MEM every 24 hrs (PBS wash) for 12 days

Trypan blue exclusion assay to determine cell viability

Figure 3: Basic culturing protocol utilized for all experimental procedures.

blue PBS solution and incubated for 5 min at room temperature. The trypan blue PBS
solution was prepared by mixing 625 µL of a 0.4% trypan blue solution with 375 µL
of PBS in a microfuge tube. The viable and dead cells were counted using a 0.11 mm
deep phase contrast hemocytometer (Hausser Scientific). Tbe cell viability was
calculated using the formula: [(total number of viable cells in the four quadrants/
total number of cells in the four quadrants) *10 *10,000].
The software package Statview was used to analyze the statistical significance
of the data and a viability dose response curve was generated using the software
package Table Curve 2D v 5.0. All experiments were done in triplicate.

Generation of 178 Estradiol and Verapamil Dose Response Curves

7F2 cells were grown to confluence in 1% FBS-supplemented OPTI-MEM
then the cells were split to 0.1 % FBS-supplemented OPTI-MEM. After 24 hrs, the
medium was switched to 0% FBS-supplemented medium following a 3 ml PBS wash.
Twenty-four hours later, the cells were fed again with 0% FBS-supplemented
medium following a 3 ml PBS wash. Subsequent washing and feeding steps were
conducted every 24 hrs for an additional 48 hrs as shown in the Figure 4. Various
concentrations of 17P estradiol or verapamil were added to the culture medium and
incubated with the 7F2 cells for 24 or 48 hrs (Figure 4). For the 48 hr experiment, the
medium volume was changed to 6 ml instead of 4 ml in order to provide additional
nutrients during the longer incubation. A minimum of 3 replicates were conducted
for each 17P estradiol and verapamil concentration studied. Both drugs were
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Figure 4: Culturing protocol for 7F2 cells exposed to 17P estradiol.
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dissolved in DMSO (Dimethyl sulfoxide, Sigma), which also served as the vehicle
control. After the drug incubation time was completed, cell viability was determined.
The cell viability was calculated using the formula: [(total number of viable cells in
the four quadrants/total number of cells in the four quadrants)* 10* 10,000].
The software package Statview was used to analyze the statistical significance
of the data and a viability dose response curve was generated using the software
package Table Curve 2D v 5.0. All experiments were conducted in triplicate.

Alkaline Phosphatase Assay

To determine if the new serum-free protocol changed the osteoblastic activity
of the 7F2 cells, an assay for the osteoblastic marker alkaline phosphatase was
performed (Figure 5). The 7F2 cells were seeded onto 24-well plates and allowed to
grow in the following media (5% FBS-supplemented DMEM, 5% FBS-supplemented
OPTI-MEM, 1% FBS-supplemented OPTI-MEM). Each medium treatment was
replicated at least six times. The medium was changed every 24 hrs and alkaline
phosphatase activity was determined on the 5th day following the initial seeding of the
wells. The wells containing 1% FBS-supplemented OPTI-MEM had their medium
replaced with 0.1 % FBS-supplemented medium after 24 hrs. After a 24 hr
incubation, the medium was replaced with serum-free OPTI-MEM for the remaining
72 hrs. All wells were fed with 1 ml of the respective medium.
After five days, the cells were fixed in 0.8% paraformaldehyde for 1 min.
After fixation, the cells were kept moist by the addition of 1 ml of 0.05% Tween in
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Figure 5: Alkaline phosphatase assay.
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PBS solution. Alkaline phosphatase assay (Chemicon) reagents were prepared
according to the manufacturer's instructions by mixing 2 parts fast violet stain, 1 part
alpha-napthol and 1 part water. After the staining solution was prepared, the Tween
solution was aspirated and the staining solution was added and incubated in the dark
at 22 °C for 15 min. After the 15 min incubation, the staining solution was aspirated
and replaced with PBS Tween. The cells were then viewed utilizing an Olympus
CKX41 inverted microscope to check for the presence of alkaline phosphatase. The
cells actively expressing alkaline phosphatase should stain red. If 90% of the cells
stain red, then the culture is positive for alkaline phosphatase.
To check the presence of alkaline phosphatase in 17P estradiol treated 7F2
cells, cultures were first seeded in 1% PBS-supplemented OPTI-MEM. After 24 hrs,
the medium was changed to 0.1 % PBS-supplemented OPTI-MEM. For the
remaining three days of incubation, the medium was changed to 0%
PBS-supplemented OPTI-MEM after a PBS wash. The presence of alkaline
phosphatase was determined following a 4 or 24 hr incubation with supplementation
of 17P estradiol (0.1 nM, 1 nM, 10 nM and 100 nM) as described above.

Immunohistochemical Localization of Osteoprotegerin

To verify the expression of osteoprotegerin (OPG) and to determine its
localization, 7F2 cells were seeded onto 6-well plates containing 22x22mm #2 glass
cover slips (Fisher) and were incubated with various concentrations of estrogen for
2 hrs (Figure 6). Cells were maintained as previously described in the generation of
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Figure 6: Protocol to visualize OPG by immunohistochemistry.
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the 17P estradiol and verapamil dose response curves. After incubation, the cells
were fixed and permeablized in ice-cold acetone for I min. The cells were then
washed three times with 0.5 % Tween in PBS for 5 min each. After washing, the
cells were incubated for 10 min with blocking solution (5% nonfat dry milk dissolved
in PBS). After blocking, cells were washed three times with 0.5 % Tween in PBS for
5 min. Primary antibody (goat anti-OPG, Santa Cruz) diluted to 1:500 in PBS was
added for 1 hr. After incubation, the primary antibody was saved for further use and
the cells were washed three times with 0.5 % Tween in PBS for 5 min. After
washing, secondary antibody (chicken anti-goat Alexa 488, Molecular Probes) was
prepared by the addition of 15 µl of the antibody to 12 ml of PBS. Secondary
antibody incubation proceeded in the dark for 30 min. After the 30 min incubation,
the cells were washed three times with 0.5 % Tween in PBS for 5 min and mounted
on glass slides (Fisher) by the addition of Ge!Mount (Fisher). Cells were visualized
utilizing an Olympus 1X71 inverted fluorescent microscope equipped with an
Imaging RETIGA EXi Fast 1394 CCD camera. Images were captured and analyzed
utilizing IP Lab software (Scanalytics). Images of the stained cells were captured at
an 850 millisecond exposure using the IPlab software to document the differences in
OPG presence between the 17P estradiol-treated groups and the control groups.
To check for non-specific binding of the secondary antibody, 7F2 cells were
stained without the addition of primary antibody. PBS was used in place of the
primary antibody in these experiments. Experiments were also conducted to
determine if 7F2 cells display autoflorescence at the wavelengths used to visualize the
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secondary antibody. In this case, PBS was used in the place of primary and
secondary antibodies. Experiments were also conducted using control cells (without
any treatment) and DMSO-treated cells (vehicle control). In addition, the A 7r5 cell
line (smooth muscle cells, American Type Culture Collection) was utilized as a
negative control.

RNA Extraction and DNAse Treatment
The 7F2 cells were maintained as described and incubated in the presence of
various concentrations of 17~ estradiol ranging form 0.1 nM to 0.5 mM for various
time intervals (1 hr, 3 hr, 6 hr, 12 hr and 24 hr). Two replicates were conducted for
each concentration and time interval. Following each incubation, cells were pelleted
by using methods explained earlier in the general protocol for culturing 7F2 cells and
resuspended in 1 mL Trizol reagent (lnvitrogen). The lysate was transferred to
microfuge tubes, combined with 200 µL of chloroform, and vortexed. The lysate was
then incubated for 3 min at room temperature. Centrifugation for 15 min at high
speed resulted in the formation of two phases. The upper, aqueous layer was pipetted
carefully into another microfuge tube, combined with 500 µL of isopropyl alcohol,
vortexed gently and incubated at room temperature for an additional 10 min. After
incubation, the microfuge tube was centrifuged for 10 min at high speed and the RNA
pellet was washed with alcohol. The pellet was resuspended in 100 µL of autoclaved, ·
distilled water and spectrophotometric readings were obtained to determine the
concentration of the RNA. At this point, 20 µg of each RNA sample was treated with
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DNAse (Promega) to remove any DNA contamination. The remainder of the RNA
was frozen for future use. The DNAse treatment was performed by adding 5 µL of
lOX DNAse reaction buffer, 20 µL of DNAse free RNAse buffer and 20 µg of RNA.
Each sample's final volume was adjusted to 50 µL by adding an additional volume of
nuclease-free distilled water. The 50 µL reaction was incubated at 37°C for 30 min.
To terminate the reaction, 5 µL of stop solution was added and incubated at 45°C for
an additional 15 min. Five microliters of sodium acetate and 50 µL of isopropanol
alcohol were added to precipitate the RNA. Samples were vortexed and centrifuged
for 10 min at maximum speed. The supernatant was discarded and the pellet washed
with 70% ethyl alcohol. After drying, the RNA pellet was resuspended in 40 µL of
nuclease-free water.

Monitoring the Expression of TIEG 6 and OPG by RT-PCR

To monitor the expression ofTIEG

~

and OPG by RT-PCR, primer sequences

were designed based on the published sequence of these genes (Table 1). Beta actin
was utilized as a control for all RT-PCR reactions. Each RT-PCR reaction consisted
of I µL of the DNAse-treated RNA, 12.5 µL Quick Access Mix (Promega), I µL
(100 ng) each of the forward and reverse gene primers, I µL (0.5 µg) of the RNA
template and 5.5 µL of nuclease-free water. To one sample for each time interval and
estrogen concentration, 0.5 µL of AMV Reverse Transcriptase was added to the
mixture and vortexed by pipetting. One sample containing all the above PCR
components, excluding the enzyme reverse transcriptase, was also prepared. This
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Table 1: OPG and TIEG pprimer sequences

OPG forward 29nt (Product SO Int)
atgaacaagtggctgtgctgtcactcct
OPG reverse 32nt (Product 50lnt)
agctgcagttggtgtgtttcctacagggtgct
TIEG ~ forward 26nt (Product 603nt)
cgtgaaagcagctagcatcctcaact
TIEG ~ reverse 25nt (Product 603nt)
ggctacagatgtgacttcttactat
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sample functioned as an RT- negative control. The RT-PCR program utilized was as
follows: 42°C for 45 min, 94°C for 2 min, 35 repeating cycles of 94°C for 30 sec,
47°C for 30 sec and 72°C for I min and a final extension of 72°C for 5 min. The
RT- PCR product was electrophoresed through a 1.6% agarose gel and visualized by
ethidium bromide staining (Figure 7).
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Figure 7: Protocol to visualize the temporal regulation of TIEG~ and OPG.

RESULTS

Weaning ofFBS and Phenol Red from 7F2 Cell Cultures
A standard tissue culture protocol involves the use of 10% PBS
supplementation, but PBS contains known quantities of estrogen (21.4 pg/ml)
(Invitrogen). In order to study the effects of estrogen on osteoblast-like cells, the
estrogenic compounds had to be removed from the culture medium. In the first set of
experiments, the 7F2 cells were weaned from PBS. Weaning the cells from PBS was
accomplished in a step-wise fashion. First the 7F2 cells were transferred to 5%
PBS-supplemented DMEM (after being split from 10% PBS-supplemented DMEM).
These cells grew to confluence within 48 hrs of splitting (Figure8B). Their
morphology and density were indistinguishable from cells that had no reduction in
PBS (compare SA and SB). The cells were then passed into 3% FBS-supplemented
DMEM. These cells grew and divided (Figure SC), but spaces remained between the
cells. These results indicate that the cells were able to grow in a small percentage of
PBS-supplemented medium, although to a lesser degree. The cells passed into 1%
PBS-supplemented DMEM (after 48 hrs) were also dividing (Figure 8D) but cell
replication was slower than in the other treatments (Figure 8). Similar results were
observed for all reduced PBS treatments when the incubation period was extended to
72 hrs (Figure 9).
Standard DMEM also contains phenol red which is reported to have
estrogenic properties (Ernst et al., 1989; Nasu et al., 2002) and thus can lead to false
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Figure 8: 7F2 cell morphology and density 48 hr after a reduction in FBS-supplementation
of culture medium (DMEM).

w
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Figure 9: 7F2 cell morphology and density 72 hr after a reduction in FBS-supplementation
of culture medium (DMEM).

positive results when studying the action of exogenous estrogen. So phenol red
should also be eliminated from the medium. The elimination of phenol red was
accomplished by switching medium from DMEM to OPTI-MEM. Cells cultured in
5% PBS-supplemented DMEM were passed to 5% PBS-supplemented OPTI-MEM.
Cells in this new medium divided rapidly and reached confluence within 72 hrs
(Figure 10). This is the same amount of time that cells grown in 5% PBSsupplemented DMEM reached confluence; thus, the absence of phenol red in the
OPTI-MEM had no effect on cell proliferation rate.
To further reduce the PBS concentration, 7F2 cells that were growing in 5%
PBS-supplemented OPTI-MEM were passed to 1% FBS-supplemented OPTI-MEM.
The cells grew to confluence within 72 hr (data not shown). To further eliminate the
presence of PBS in the medium, cells grown to confluence in the 1%
PBS-supplemented OPTI-MEM were passed to even lower concentrations of
PBS-supplemented OPTI-MEM (0.5, 0.25, 0.1, 0.05 and 0%). Twenty-four hours
after transfer to a medium containing a reduced concentration of PBS, cells in all the
treatments were adherent to the flasks and undergoing cell division as evidenced by
the colony expansion (Figure 11). Of particular interest was the fact that 7F2 cells
exposed to 0% PBS-supplemented OPTI-MEM were attached, stretching out, and
dividing (Figure l IE). Further incubation for either a total of 48 or 72 hrs (Figure 12
and 13, respectively) revealed that cells in all treatments maintained their health and
were continuing to divide. Cells in all treatments reached confluence, even in the
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Figure 10: Transfer of 7F2 cells from 5% FBS- supplemented DMEM to
5% FBS-supplemented OPTI-MEM.

Figure 11: 7F2 cell morphology and density 24 hours after a reduction in FBS-supplementation of culture
medium (OPTI-MEM).

Figure 12: 7F2 cell morphology and density 48 hours after a reduction in FBS-supplementation of culture
medium (OPTI-MEM).

Figure 13: 7F2 cell morphology and density 72 hours after a reduction in FBS-supplementation of
culture medium (OPTI-MEM).

treatment devoid of PBS (Figure 12E and 13E). Clearly, neither PBS, nor phenol red,
is required for cell division in the 7F2 cell line.

Cell Viability of 7F2 Cells Cultured in O% FBS for Two Weeks

The 7F2 cell line survived/divided over a 72 hr in a medium devoid of PBS,
but it was necessary to see whether they remain viable for a prolonged period of time
in this medium. Cells grown in 1% PBS-supplemented OPTI-MEM (Figurel4A)
were split into small flasks containing 0.1 % PBS supplemented medium as illustrated
in Figure 3. Twenty-four hours after passage and exposure to 0.1 %
PBS-supplemented OPTI-MEM, cells were adherent (Figure 14B). The cells were
then transferred to OPTI-MEM devoid of FBS. After an additional 24 hr culture
period, now in 0% PBS, the cells were clearly undergoing mitosis (Figure 14C).
Cells were feed every 24 hr with 0% PBS-supplemented OPTI-MEM and the culture
status was documented with a representative micrograph. For each day up to Day 13
(Figures 14, 15, 16) cell viability assays were conducted. When mean cell viability
was compared between the days of the experimental period a significant difference
(p=0.0436) was observed. However, cell viability remained above 93% throughout
the experimental period for all cultures analyzed (Figure 17). Thus the cells can
survive and maintain high cell viability for a prolonged period in a PBS-devoid
environment.
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Figure 14: Maiutenance of a low estrogen environment for the expansion of 7F2 cultures
in OPTI-MEM, Days O though 5.

Figure 15: Maintenance of a low estrogen environment for the expansion of 7F2 cultures
in OPTI-MEM, Days 6 though 11.

Figure 16: Maintenance of a low estrogen environment for the expansion of 7F2 cultures in
OPTI-MEM, Days 12 though 13.
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Figure 17: Cell viability of 7F2 cells determined by trypan blue exclusion for cells
cultured for two weeks in 0% FBS-supplemented OPTI-MEM.

Alkaline Phosphatase Activity in the of 7F2 Cell Line

To check whether the osteoblastic nature of the 7F2 cells had been altered by
the new protocol, the presence of the osteoblastic marker alkaline phosphatase was
monitored. The 7F2 cells grown in 5% FBS-supplemented DMEM (Figure ISA), 5%
FBS-supplemented OPTI-MEM (Figure ISB), I% FBS-supplemented OPTI-MEM
(Figure !SC), and 0% FBS-supplemented OPTI-MEM (FigurelSD) all demonstrated
the presence of alkaline phosphatase in greater than 90% of cells visualized. The
presence of alkaline phosphatase in the 7F2 cell line suggests that its osteoblastic
nature was not changed by the developed cell culture protocol.

Immunohistochemical Localization of OPG

To further verify that the osteoblastic nature of the 7F2 cells had not been
altered by the new protocol, the presence of the osteoblastic marker like OPG was
monitored. The 7F2 cells grown in 0% FBS-supplemented OPTI-MEM were stained
for OPG. As evident in Figure 19A, the cells contain the osteoblastic marker OPG,
and that it is localized throughout the cytoplasm. To demonstrate the specificity of
OPG to 7F2 cells, A7r5 smooth muscle cells were also stained for OPG. As indicated
in Figure 19B, A7r5 cells do not exhibit staining for OPG. Two negative controls
were also conducted: one is which no primary antibody was added and one in which
no primary or secondary antibody was added. These controls reveal some
autoflorescence, but that it is restricted to the nucleus (Figure !9C and D).
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Figure 18: Alkaline phosphatase detection in 7F2 cultures exposed to varying concentrations of FBS
in 2 different media (DMEM and OPTI-MEM).
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Figure 19: Visualization of OPG in 7F2 and A7r5 cultures. Controls are also included.

Effect of Exogenous 176 estradiol on 7F2 Cell Cultures
Estrogen is considered to induce osteoblastic effects, so an experiment was
performed to check whether estrogen alters the proliferation of cultured 7F2 cells.
Cells grown in 1% PBS-supplemented OPTI-MEM were split into small flasks
containing 0.1 % PBS-supplemented OPTI-MEM. Twenty-four hours later, the cells
were switched to 0% PBS-supplemented OPTI-MEM, after a PBS wash. On the
following day, fresh 0% PBS-supplemented OPTI-MEM was added. Once the cells
had been cultured for 48 hrs in 0% PBS-supplemented OPTI-MEM, various
concentrations of estrogen were added. Cell viability was assessed after the cells had
been incubated for 24 and 48 hrs.
After 24 hrs, estrogen-treated cells did not show any change in cell
morphology, when compared to the vehicle control (DSMO) (Figure 20). In
17~ estradiol treatments less than 0.2 mM, the medium remained transparent and the
cells demonstrated normal morphology. At the higher concentrations of 1 mM to
1.9 mM (Figure 20E and F, respectively) the medium became cloudy due to supersaturation with 17~ estradiol, however this apparently did not influence cell division.
Data from the 24 hr period indicates that 7F2 cells can survive in 17~ estradiol
concentrations as high as 1.9 mM with no significant loss in cell viability (p=0.346)
(Figure 21 ).
After 48 hrs of incubation, many of the higher 17~ estradiol concentration
treatments (above 25 µM) exhibited significant toxicity (p<0.0001). At
concentrations at, or exceeding 100 µM, viability was very low (between 0% and
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Figure 20: 7F2 culture responsiveness to increasing concentrations of 17~ estradiol after incubation for 24 hrs.
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Figure 21: Viability curve for 7F2 cells exposed for 24 hrs to various
concentrations of 17 pestradiol.

80%) (Figure 23) and the cells were detached and rounded up (Figure 22E). In
between 25 µM and 100 µM, viability was quite variable ranging from 0% to 80%
(Figure 23). Cells treated with the vehicle control (DMSO) (Figure 22A) showed no
apparent adverse effects having cell viability values equal to the untreated controls.
These results indicate that the 17P estradiol exhibits no toxicity on the 7F2 cell line
after 24 hrs and that the cells continue to proliferate just like the controls. After
increasing the incubation period to 48 hrs, it was observed that 17P estradiol does
elicit a toxic effect on the cells and decreases cell proliferation rate.

Alkaline Phosphatase Activity in the 7F2 Cell Line after Incubation with 178
Estradiol
To check whether the expression of alkaline phosphatase, an osteoblastic
marker, continues to be produced by 7F2 cells following exposure to 17P estradiol,
cells were treated with various concentrations of 17P estradiol for different time
intervals. The 7F2 cells, exposed to 0.1 nM, 1 nM, 10 nM, and 100 nM 17P estradiol
for either 4 hr or 24 hrs, all demonstrated the presence of alkaline phosphatase in
greater than 90% of the cells visualized (Figures 24 and 25, respectively). The
vehicle control (DMSO) did not alter the expression of alkaline phosphatase in either
time frame (Figure 24A and 25A, respectively). The results indicate that the 7F2
cells continue to express alkaline phosphatase when exposed to 17P estradiol.
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Figure 22: 7F2 culture responsiveness to increasing concentrations of 17~ estradiol after incubation for 48
hrs.
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Figure 23: Viability curve for 7F2 cells exposed for 48 hrs to various
concentrations of 17~ estradiol.
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Figure 24: Detection of alkaline phosphatase in 7F2 cultures with increasing concentrations of
17P estradiol after incubation for 4 hrs.
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Figure 25: Detection of alkaline phosphatase in 7F2 cultures with increasing concentrations of
17P estradiol after incubation for 24 hrs.

Immunohistochemical Localization of OPG after Incubation with 178 Estradiol
To check whether the expression of OPG, an osteoblastic marker, is
maintained by 7F2 cells following exposure to 17P estradiol, cells were treated with
various concentrations of 17P estradiol. OPG was detected in cultures exposed to
1 nM, 10 nM and 100 nM 17P estradiol (Figure 26B-D). As expected, OPG appears
to be localized to the cytoplasm of the cell. However, due to autoflorescence in the
nucleus (see Figure 19D), quantitative analysis was not possible. Examination of the
micrographs indicates evidence of a possible translocation of OPG within the cell
which might suggest its movement to the cell periphery for possible secretion. The
expression of OPG indicates that the 7F2 cells retain their osteoblastic nature after
incubation with various concentrations of 17P estradiol.

Temporal Regulation of OPG and TIEG8 Expression after Incubation with
Various Concentrations of 178 estradiol
To check for the presence of 17P estradiol responsive genes like OPG and
TIEG p in the 7F2 cell line, cells were treated with various concentrations of 17P
estradiol. The presence of gene expression was detected using RT-PCR. Following
an incubation of 3 hrs with various concentrations of estrogen (0.1 nM to 500 µM),
the presence of an OPG transcript was detected in all treatments, except the JOO µM
17P estradiol treatment and the DMSO control (Figure 27). The expression of OPG
was expected in the DMSO control based on the immunohistochemical results. Its
absence might be due to some artifact. Additional experimentation utilizing the same
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Figure 26: Visualization of OPG in 7F2 cultures exposed to 17~ estradiol after incubation
for 2 hrs.
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Figure 27: Temporal regulation of OPG in 7F2 cultured cells.
1= l00bp DNA Ladder; 2= Controls; 3= DMSO; 4= 0.1 nM ; 5= 1 nM;
6= 10 nM; 7= 100 nM; 8= 1 µM, 9= 10 µM; 10= 100 µM
11=500 µM.
+ = presence of Reverse Transcriptase
- = absence of Reverse Transcriptase

estrogen concentrations were conducted at various time intervals (1 hr, 6 hrs, 12 hrs
and 24 hrs) but the OPG transcript was not detected (data not shown). The positive
control P actin was present in all the samples.
The expression of an additional 17P estradiol responsive gene (TIEG Pl was
also monitored following exposure of the cells to 17P estradiol concentrations ranging
from 100 µM to 500 µM for various time intervals (1 hr, 3 hrs, 6 hrs, 12 hrs and
24 hrs). TIEG P expression was detected at every time interval (Figure 28) except
12 hrs. The presence of P actin was also analyzed as a positive control and was
detected at every time interval. In order to test for DNA contamination, the presence
of p actin was analyzed in samples in which no reverse transcriptase activity was
present (Figure 28). In the samples without reverse transcriptase,

p actin was not

detected. This indicates that there was no contamination of the RNA samples with
DNA. These results indicate that OPG and TIEG

p are both expressed by 7F2 cells

treated with 17P estradiol confirming the osteoblastic nature of these cells. Although
there are differences in band intensities, this assay is only qualitative, not quantitative.

Effects ofVerapamil on 7F2 Cell Cultures
To investigate the effect of calcium channel antagonists on the 7F2 cell lines,
cells were treated with various concentrations of verapamil. After 24 and 48 hrs, the
cell proliferation was assessed. The 7F2 cells treated with DMSO and various
concentrations of verapamil (10 µM - 500 µM) for a 24 hr period did not demonstrate
deleterious effects such as detachment or rounding up until the concentration of
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Figure 28: Temporal regulation of TIEG 1J in 7F2 cultured cells.
1= l00bp DNA Ladder; 2= Controls; 3= DMSO; 4= 0.1 nM ; 5= 1
nM; 6= 10 nM; 7= 100 nM; 8= 1 µM, 9= 10 µM; 10= 100 µM
11= 500 µM.
There is no DMSO sample present in the 1 hr incubation.
+ = presence of Reverse Transcriptase
- = absence of Reverse Transcriptase
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verapamil exceeded 500 µM (Figure 29). Cell viability assays (Figure 30) supported
the visual observations in that concentrations exceeding 500 µM were toxic to 7F2
cells. Statistical analysis indicated that concentrations above 500 µM significantly
reduced cell viability (p<0.0001).
Incubation of 7F2 cells for 48 hrs with various concentrations of verapamil
(25 µM -150 µM) did not display detachment until the concentration exceeded
125 µM (Figure 31D). Viability data (Figure 32) indicated a reduction in viability
starting at 175 µM, with complete cell death by 500 µM. Statistical analysis
indicated that concentrations above 200 µM significantly reduced cell viability
(p<0.0001). These results indicate that veramapil does not support the proliferation
of 7F2 cells at concentrations greater than 125 µM after 48 hrs of incubation. At
lower concentrations, 10 µM-100 µM, cell viability was apparently unaffected by the
presence of verapamil.
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Figure 29: 7F2 culture responsiveness to increasing concentrations of verapamil after incubation for 24 hrs.
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Figure 30: Viability curve for 7F2 cells exposed for 24 hrs to various concentrations
of verapamil.

0\
00

Figure 31: 7F2 culture responsiveness to increasing concentrations of verapamil after
incubation for 48 hours.
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Figure 32: Viability curve for 7F2 cells exposed for 48 hrs to various
concentrations of verapamil.

DISCUSSION

The purpose of this project was to study the effect of 17P estradiol and
veraparnil on osteoblast-like cells (7F2). Standard tissue culture medium contains
phenol red and is supplemented with FBS. Phenol red may be estrogenic (Ernst et al.,
1989; Nasu et al., 2002) and FBS contains known quantities of estrogen (Invitrogen).
It is only logical to assume that the use of these estrogenic compounds, if not required
for cell viability, could lead to the false interpretation of results. Thus, there is a need
to reduce/eliminate these estrogenic compounds from the tissue culture medium in
order to allow a proper investigation of the effects 17P estradiol has on the osteoblastlike cell line 7F2.
In order to reduce the amount of estrogenic elements that 7F2 cells were
exposed to, cells were grown in a reduced FBS environment. The weaning of cells
from FBS at 10% to 1% in DMEM did not result in any change in gross cell
morphology or cell viability after 48 or 72 hrs (Figures 8-10). To eliminate the
potential estrogenic compound phenol red from the culture medium, the medium was
switched from DMEM to OPTI-MEM. OPTI-MEM is an enriched phenol red-free
medium. The change from DMEM to OPTI-MEM did not affect the proliferation and
attachment of the cells after 24, 48 and 72 hrs (Figure 10), as long as at least 0.1 %
FBS was present. When the level of FBS in the OPTI-MEM was reduced to zero, the
cells continued to actively proliferate (Figure 12E), but the rate of mitosis after 72 hrs
was slower than in the other FBS-supplemented media. It appears that these cells
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need a small amount to PBS (which contains growth factors) to initiate cell
attachment and to stimulate cell division. Thus, in order to maintain these cells as a
stock culture, the cells were grown in a medium supplemented with 1% PBS in order
to maintain a rapid rate of cell proliferation.
As previously stated, the 7F2 stock culture was maintained in OPTI-MEM
(devoid of phenol red) and in the presence of 1% PBS. The level of PBS present in
the medium could be further reduced by weaning the cells to 0.1 %
PBS-supplemented medium and then to 0% PBS-supplementation with no reduction
in viability for 72 hrs. Additional experiments were carried out to determine whether
the 7F2 cells would maintain the cell viability for 2 weeks. In the 0%
PBS-supplemented medium (in a minimal estrogen environment) the cells continued
to proliferate and express high cell viability for 13 days. The cell proliferation rate
increased after Day 2, reached confluence at Day 4, and confluence was maintained
for at least 13 days (Figure 17). There was a significant difference (p< 0.05) in the
cell viability across the 13 day experimental period because the mean cell viability for
Days 4 and 11 were much higher than the means for the other days. However, it must
be noted that the viability for all days of the experimental period was higher than
93%. This indicates that the cells were viable for a two week period in the absence of
PBS. Thus, PBS is not required for 7F2 cell proliferation in OPTI-MEM, but cell
proliferation occurs at a slower rate. There is no other reported protocol that provides
such a substantial reduction in estrogenic compounds. That makes this protocol well
suited to investigate the role of 17~ estradiol in the osteoblast-like the 7F2 cell line ..
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The protocol was designed to reduce estrogen levels in the medium as much as
possible. All known estrogenic compounds were removed from the medium and all
cell feedings involved wash steps to remove residual estrogenic compounds from
surfaces. It is possible that trace amounts of estrogenic compounds remain. For this
reason, terminology such as "absence of added estrogen" is used instead of "absence
of estrogen".
Such a dramatic change from the standard cell culture protocol may have
altered the osteoblastic nature of the 7F2 cells, and thus, could lead to erroneous
interpretation of the data. Mature osteoblasts, like these 7F2 cells, should be able to
secrete alkaline phosphatase, an osteobastic marker (Majeska et al., 1994), as alkaline
phosphatase is a required component in bone mineralization (Manolagas, 2000).
When the 7F2 cells were cultured in different concentrations of
PBS-supplemented medium both in the presence (5% DMEM) and absence of phenol
red (5% OPTI-MEM, 1% OPTI-MEM and 0% OPTI-MEM), all cultures
demonstrated the production of alkaline phosphatase (Figure 18). The presence of
alkaline phosphatase in cells cultured in both the 1% PBS-supplemented OPTI-MEM
medium and 0% PBS-supplemented OPTI-MEM indicate that a reduction in PBS
(and estrogen) does not alter the osteoblastic nature of these cells. The 7F2 cells
continued to express alkaline phosphatase in the absence of estrogen suggesting that
these cells would be able to perform their bone mineralization duties.
17~ estradiol is reported to upregulate alkaline phosphatase activity in
osteoblast-like cells in a dose-dependent manner (Gray et al., 1987; Majeska et al.,
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1994). This provides evidence that 17P estradiol is an important mediator of
mineralization in bone. 7F2 cells incubated with various concentrations of
17P estradiol for 4 and 24 hrs expressed alkaline phosphatase. Thus, 7F2 cells
exposed to 17P estradiol continue the production of alkaline phosphatase in the newly
described medium. 17P estradiol did not suppress the bone mineralization process of
the osteoblast-like cells. Unfortunately, as the colorimetric assay is only qualitative,
the level of alkaline phosphatase expression could not be compared among the
different estrogen concentrations nor among the different incubation periods.
Another important osteoblastic marker is OPG, a member of TNF
superfamily. OPG acts as a decoy receptor to RANKL and inhibits the interaction
between the RANK and RANKL (Figure 33) (Stejskal et al., 2002; Bord et al., 2003).
OPG's secretion by osteoblasts is an important means by which osteoblasts regulate
osteoclastogenesis, because OPG is a potent inhibitor of osteoclastogenesis both in

vivo and in vitro (Simonet, et al., 1997). Therefore, OPG is seen as an important
osteoblastic bone cell marker.
Consistent with the previous findings that osteoblasts produce OPG, the 7F2
cells cultured according to the reduced-estrogen protocol also produce OPG. These
results would suggest that the new protocol did not alter the osteoblastic nature of the
7F2 cells. Immunohistochemical localization of OPG suggests that it is present in the
cytoplasm. The absence of OPG (Figure 19B) in the A7r5 smooth muscle cell line,
demonstrates the specificity of OPG to osteoblasts.
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Figure 33: Interaction of OPG with RANKL stops the interaction of RANK and RANKL.

Downregulation of OPG leads to osteoporosis in OPG-knockout mice (Bucay

et al,. 1998). Interestingly, the over expression of OPG also causes osteopetrosis
(Simonet et al., 1997; Karsenty, 1999). Since under and over-production are both
disease forming, there must be a complicated control mechanism for OPG
production/secretion in osteoblasts. This regulation would allow proper maintenance
of osteoblastic activity.
In the process of bone remodeling one of the mechanisms of regulation is to
control the OPG!RANKL ratio by estrogen. Estrogen has been reported to increase
the OPG/RANKL ratio (Stejskal et al., 2002) explaining the antiresorptive effects
associated with estrogen. Consistent with the literature, this study found that estrogen
maintains the expression of OPG in 7F2 cell cultures. As illustrated in Figures
26B-D, treatment with various concentrations of estrogen is associated with OPG
expression. It appears that in the 100 nM 17~ estradiol treatment, there is a
redistribution of OPG towards the periphery of the cell membrane which would be of
interest to examine further since it suggests OPG secretion. Problems with
autofluorescence (Figure 19D) prevented quantitative comparisons between the
17~ estradiol treatments and the controls.
Cells incubated for 24 hrs in various concentrations of 17~ estradiol display
no significant difference in the cell viability (p>0.5) indicating that the steroid
hormone does not elicit a toxic effect on the cultured cells. Various studies have
suggested that 17~ estradiol can either increase (Ernst Met al., 1988), decrease (Gray

et al., 1987), or have no effect (Keeting et al., 1991) on the proliferation of
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osteoblastic cells. Our findings suggest that estrogen does not impact the viability of
the 7F2 cells over a wide range of concentrations (0.1 nM to 1.9 mM).
However, when the incubation time was increased to 48 hrs 17P estradiol
concentrations above 25 µM had toxic effects on the 7F2 cells; and at 100 µM cell
death was initiated. As can be seen in Figure 23, there was great variability in the
viability results between 25 µM and 100 µM of estrogen as the percentages ranged
from 80% - 0%. This does not indicate experimental error, since the experimental
controls performed on the same days were also statistically different from all the
other controls. These results may indicate that estrogen has a time-dependent effect
on the osteoblasts.
In an attempt to validate the results from immunohistochemical localization of
OPG, OPG transcripts were also detected for a wide range of 17P estradiol
concentrations ( 100 µM to 500 µM). Cells incubated with various concentrations of
estrogen for 3 hrs produced OPG transcripts (Figure 27). This may indicate that
estrogen maintains its anti-resorptive activity via the production of OPG. OPG acts
by blocking the differentiation of osteoclasts from osteoclast progenitors and thus
inhibits resorption. The expression of the OPG transcript corroborated the
observations from the immunohistochemical data. The presence of OPG transcripts
were not detected after any other incubation interval (1 hr, 6 hrs, 12 hrs, 24 hrs). This
suggests that the OPG transcript is not expressed quickly following estrogen exposure
and that its expression is short-lived.
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To detect the presence of another 17P estradiol responsive gene, TIEG P
mRNA was detected. TIEG p is a member of the Transforming Growth Factor p
(TGF P) family. Hugest et al. (1996) reported that estrogen induces apoptosis of
osteoclasts both in vitro and in vivo via the production of TGF p. The suspected role
of TIEG p is to help maintain the anti-resorptive effects of 17P estradiol by targeting
osteoclasts for apoptosis. The presence of TIEG PmRNA in the 7F2 cell line
(Figure 28) indicates that, after 17P estradiol treatment, TIEG p expression is
maintained. These results may be suggesting that 17P estradiol induces TIEG

p

production in 7F2 cell lines in order to maintain these anti-resorptive activities. The
presence of TIEG p transcript after 1 hr of estrogen treatment indicates that TIEG p is
expressed very early. The presence of TIEG

p after 24 hrs indicates that the TIEG p

transcript either has a longer half-life than OPG or is continuously expressed. The
expression of TIEG

p was not seen in all the concentrations tested suggesting that

TIEG p expression is dose-dependent.
Guggnio et al. (1989) suggested that calcium channel blockers
(e.g., verapamil, nifedipine) interfere with bone resorption. In the present study,

treatment of the 7F2 cell line with the calcium channel antagonist verapamil
(at concentrations ranging from 10 µM - 500 µM) produced no toxic effects after 24
hrs. Following a 48 hr incubation, however, only verapamil concentrations below
150 µM were not lethal to the 7F2 cell line. This data indicates that verapamil is
toxic to the osteoblasts in a dose-dependent manner. These results confirm that
calcium channel function is required for cell viability.
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CONCLUSIONS

The results indicate that osteoblast-like cells (7F2 cells) can be cultured in a
medium devoid of the estrogenic compounds FBS and phenol red. The 7F2 cells
cultured in a FBS- and phenol red-free environment, for as long as 2 weeks, did not
show any decrease in cell proliferation nor express altered morphology. This
suggests that the 7F2 cells can even proliferate for a longer time period in a FBS-free
and phenol red-free environment.
In order to ensure that these cells retained their osteoblastic nature in this new
medium, two osteoblast specific markers were assessed. The first marker, alkaline
phosphatase, was assessed utilizing a colorimetric assay. 7F2 cells in both the newly
developed and standard protocols expressed this marker. The second marker, OPG,
was assessed using immunohistochernical techniques. The 7F2 cells also expressed
the presence of the OPG marker. Both of these colorimetric and
immunohistochernical techniques provide evidence that the new protocol did not alter
the osteoblastic nature of the cells.
Hence, a cell culture protocol was developed in which osteoblast-like cells can
be cultured in an environment substantially reduced in estrogenic compounds.
Furthermore, these cells retain their osteoblast-like nature, allowing current and future
investigations into estrogen's role in skeletal metabolism.
7F2 cells cultured according to the newly developed protocol demonstrated
that 17~ estradiol did not have any effect on the cell proliferation of 7F2 cells
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following an incubation of 24 hrs in a wide range of concentrations. However, after
48 hrs of incubation in 17P estradiol, cell death was observed in some of the
17P estradiol concentrations. Some of the concentrations utilized were toxic after 48
hrs, but not after 24 hrs, suggesting a time-dependent effect of 17P estradiol on the
osteoblast-like cells.
Cultures exposed to 17P estradiol exhibited no change in OPG localization or
gene expression and alkaline phosphatase production was maintained. RT-PCR data
suggests that 17P estradiol at most of the concentrations did not influence the
expression of the osteoblast-specific genes (OPG and TIEG-P). The results from the
various experiments involving 17P estradiol indicate that this steroid hormone does
not alter the osteoblastic activity of the 7F2 cells. Due to limitations in the techniques
utilized, quantification of protein and mRNA levels could not be accomplished.
Since the regulation of calcium exchange through bone cells is of
considerable interest, the ability to employ calcium channel antagonists to investigate
their potential impact on osteoblast-like cells was critical. The experimental findings
suggest that veramapil, a calcium channel antagonist, decreases osteoblast cell
proliferation in a dose-dependent fashion.
These experimental findings indicate that the culture protocol developed did
not alter the osteoblast-like nature of the 7F2 cell line and also illustrated that
17P estradiol did not hinder the apparent osteoblastic activity of the 7F2 cells. The
results also suggest a dose-dependent response of 17P estradiol and veraparnil on
osteoblast cell proliferation. Thus, the newly developed protocol provides a model
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system to study the anti-resorptive role of estrogen on skeletal turnover and provides
a potential avenue to investigate the impact of calcium channel antagonists or other
compounds on estrogen's mechanism of action.
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